Molecular Targets in Inflammatory Breast Cancer
Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses molecular targets in inflammatory breast cancer.
Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses molecular targets in inflammatory breast cancer (IBC).
Clinical Pearls:
- Inflammatory breast cancer (IBC) remains a very aggressive cancer and women with the disease only live for a limited amount of time
- A lack of dedicated IBC trials is preventing researchers and physicians from determining novel pathways to target
- New discoveries about the biology of IBC has led researchers and physicians to understand pathways that are activated in the disease
- Studies have found that the PI3/AKT/mTOR pathway is activated in cell lines with IBC and xenograft models
- Tumor-associated macrophages cause activation of cytokines that leads to upregulation of the JAK-STAT pathway. Upregulation of this pathway leads to cell proliferation and survival
- Results of animal trials have shown overall survival benefit when both the PI3/AKT/mTOR pathway and the JAK-STAT pathway were inhibited
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
